BionTech And Oncoc4 Say The First Non-small Cell Lung Cancer Patient Has Been Treated In A Pivotal Phase 3 Trial Of BNT316/ONC-392 (Gotistobart); The Trial Is Part Of Biontech's Strategy To Initiate Multiple Pivotal Trials In 2023 & 2024
Portfolio Pulse from Benzinga Newsdesk
BionTech and Oncoc4 have announced the treatment of the first non-small cell lung cancer patient in a pivotal Phase 3 trial of BNT316/ONC-392 (Gotistobart). This trial is part of BionTech's strategy to initiate multiple pivotal trials in 2023 and 2024.
June 29, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BionTech's initiation of a Phase 3 trial for BNT316/ONC-392 could potentially boost its stock as it indicates progress in their product pipeline.
The initiation of a Phase 3 trial is a significant milestone in drug development. This news indicates progress in BionTech's product pipeline, which could positively impact investor sentiment and potentially boost the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100